02:31 PM EDT, 10/25/2024 (MT Newswires) -- ImmunityBio ( IBRX ) shares soared 66% in recent trading Friday after the company reported Thursday dosing of the first patients in a phase 1 trial that will assess its CAR-NK cellular therapy as a potential treatment for non-Hodgkin's lymphoma.

Over 43 million shares traded intraday versus a daily average of roughly 2.9 million.

BM Technologies ( BMTX ) said Friday it has struck a deal for First Carolina Bank to buy the firm for $5 a share in cash with an equity value of about $67 million.

Shares surged 47% as intraday trading volume advanced to more than 2.9 million from a daily average of about 46,000.

Iterum Therapeutics ( ITRM ) said Friday that the US Food and Drug Administration approved its new drug application for Orlynvah to treat uncomplicated urinary tract infections in women.

Shares soared 60% as intraday trading volume catapulted to over 86.1 million from a daily average of about 315,000.

Price: 7.00, Change: +2.79, Percent Change: +66.22